TY - JOUR T1 - SARS-CoV-2 transmission, vaccination rate and the fate of resistant strains JF - medRxiv DO - 10.1101/2021.02.08.21251383 SP - 2021.02.08.21251383 AU - Simon A. Rella AU - Yuliya A. Kulikova AU - Emmanouil T. Dermitzakis AU - Fyodor A. Kondrashov Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/10/2021.02.08.21251383.abstract N2 - Vaccines are thought to be the best available solution for controlling the ongoing SARS-CoV-2 pandemic1,2. However, the emergence of vaccine-resistant strains3–6 may come too rapidly for current vaccine developments to alleviate the health, economic and social consequences of the pandemic7,8. To quantify and characterize the risk of such a scenario, we created a SIR-derived model9,10 with initial stochastic dynamics of the vaccine-resistant strain to study the probability of its emergence and establishment. Using parameters realistically resembling SARS-CoV-2 transmission, we model a wave-like pattern of the pandemic and consider the impact of the rate of vaccination and the strength of non-pharmaceutical intervention measures on the probability of emergence of a resistant strain. We found a counterintuitive result that the highest probability for the establishment of the resistant strain comes at a time of reduced non-pharmaceutical intervention measures when most individuals of the population have been vaccinated. Consequently, we show that a period of transmission reduction close to the end of the vaccination campaign can substantially reduce the probability of resistant strain establishment. Our results suggest that policymakers and individuals should consider maintaining non-pharmaceutical interventions7,11,12 throughout the entire vaccination period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementETD is supported by the Swiss National Science and Louis Jeantet Foundation. The work of FAK was in part supported by the ERC Consolidator grant (771209-CharFL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval for our study was necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results of our modeling are reported in the manuscript in full and the primary code is available on Github https://github.com/Simon-Re/mut-vacc ER -